Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heikki Joensuu

Showing results (1-10 of 307) with videos related to

Pageof 31
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|January 14, 2003
[Tyrosine kinase inhibitor as a targeted therapy for GIST tumors]Heikki Joensuu
Cancer Treatment Reviews|November 21, 2016
Escalating and de-escalating treatment in HER2-positive early breast cancerHeikki Joensuu
The New England Journal of Medicine|January 20, 2017
Adaptive Randomization of Neratinib in Early Breast CancerHeikki Joensuu
Drugs|September 22, 2012
Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal managementHeikki Joensuu
Human Pathology|September 9, 2008
Risk stratification of patients diagnosed with gastrointestinal stromal tumorHeikki Joensuu
The Lancet. Oncology|March 1, 2011
HERA crosses overHeikki Joensuu
Lancet (London, England)|December 18, 2007
Cardiac toxicity of sunitinibHeikki Joensuu
The Lancet. Oncology|March 1, 2008
Systemic chemotherapy for cancer: from weapon to treatmentHeikki Joensuu
Lancet (London, England)|October 19, 2006
Sunitinib for imatinib-resistant GISTHeikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|December 6, 2012
[Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses]Heikki Joensuu
Pageof 31

Showing results (1-10 of 307) with videos related to

Sort By:
Pageof 31
Duodecim; Laaketieteellinen Aikakauskirja|January 14, 2003
[Tyrosine kinase inhibitor as a targeted therapy for GIST tumors]Heikki Joensuu
Cancer Treatment Reviews|November 21, 2016
Escalating and de-escalating treatment in HER2-positive early breast cancerHeikki Joensuu
The New England Journal of Medicine|January 20, 2017
Adaptive Randomization of Neratinib in Early Breast CancerHeikki Joensuu
Drugs|September 22, 2012
Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal managementHeikki Joensuu
Human Pathology|September 9, 2008
Risk stratification of patients diagnosed with gastrointestinal stromal tumorHeikki Joensuu
The Lancet. Oncology|March 1, 2011
HERA crosses overHeikki Joensuu
Lancet (London, England)|December 18, 2007
Cardiac toxicity of sunitinibHeikki Joensuu
The Lancet. Oncology|March 1, 2008
Systemic chemotherapy for cancer: from weapon to treatmentHeikki Joensuu
Lancet (London, England)|October 19, 2006
Sunitinib for imatinib-resistant GISTHeikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|December 6, 2012
[Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses]Heikki Joensuu
Pageof 31